Clinical Trial Update: Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating nimotuzumab in combination with paclitaxel for recurrent/metastatic gastric cancer or esophagogastric junction adenocarcinoma. The st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Junction Adenocarcinoma
• Gastric Cancer

Drugs mentioned

• Nimotuzumab (nimotuzumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Biotech Pharmaceutical Co., Ltd. | Conditions: Gastric or Esophagogastric Junction Adenocarcinoma | Phase 3 | Status: RECRUITING